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Abstract
Background: Efficacious immune-based therapy in treated chronic HIV-1 infection requires the induction of virus-specific
CD4+ T cells and subsequent maturation and maintenance of specific memory CD8+ T cells. Concomitant daily administration
of recombinant human growth hormone (rhGH) with highly active antiretroviral therapy (HAART) was used in chronically
infected patients with lipodystrophy in an attempt to reconstitute these virus-specific T-cell responses.
Methods: Individuals with chronic HIV-1 infection on HAART were enrolled on a randomized, double-blinded, placebo-
controlled study to receive rhGH therapy. We assessed HIV-1-specific proliferative CD4+ and interferon-gamma (IFN-γ)-
producing CD8+ T-cell responses, quantified thymic output and proviral HIV-1 DNA at the following time points: baseline; after
12 weeks of rhGH therapy; at 24 weeks, after randomization into three groups [placebo weeks 12–24 (Group A), alternate-day
dosing weeks 12–24 (Group B), and twice-per-week dosing weeks 12–24 (Group C)]; and at 48 weeks after all patients had
received HAART alone for the final 24 weeks.
Results: We found significant increases in both proliferative CD4+ and IFN-γ-producing CD8+ HIV-1-specific T-cell responses
after daily administration of rhGH. This increase was focused on HIV-1 Gag-specific T-cell responses. Following subsequent
randomisation into different dosing regimens, HIV-1-specific proliferative CD4+ T-cell responses declined in patients receiving
less frequent dosing of rhGH, while virus-specific IFN-γ-producing CD8+ T-cell responses were maintained for longer periods
of time. There was no significant change in thymic output and the cell-associated HIV-1 DNA remained stable in most patients.
An increased anti-HIV-1 Nef-specific CD4+ T-cell proliferative response was correlated to a decrease in proviral load, and an
increased HIV-1 Gag-specific IFN-γ-producing CD8+ T-cell response correlated with an increase in proviral load.
Conclusion: The implication of these data is that daily dosing of rhGH with HAART, in addition to improving HIV-1-associated
lipodystrophy, may reverse some of the T-lymphocyte dysfunction seen in most treated HIV-1-positive patients, in a dose-
dependent manner. Such immune-based therapeutic strategies used in treated, chronic HIV-1 infection may enable the induction
of virus-specific CD4+ T cells essential for the subsequent 'kick-start' and expansion of virus-specific CD8+ T cells.
Trial registration: GH in Lipoatrophy IMP22350.
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Infection with HIV-1 causes a severe down-regulation of
virus-specific CD4+ and CD8+ T cells that is not restored
upon treatment with highly active antiretroviral therapy
(HAART). The aims of immune-based therapeutic inter-
ventions in the presence of HAART are to deplete viral
burden in cellular reservoirs, to induce and maintain
virus-specific responses, and to facilitate regeneration of
the immune system; thereby allowing the HIV-1-infected
individual to control viral replication and opportunistic
pathogens in the absence of drug therapy [1,2]. One can-
didate molecule to include as part of such an intervention
is growth hormone (GH). GH exerts stimulatory effects on
different cells of the immune system, mediated either
directly or indirectly through insulin-like growth factor-1
[3-5], and has implications in T-lymphocyte development
and function [6]. This suggests a role for recombinant
human growth hormone (rhGH) as a possible immu-
nomodulatory therapy, complimentary to the benefits of
effective antiretroviral drug therapy, for HIV-1 infection
[5]. Furthermore, studies in both HIV-1-infected adults
and adolescents with lipodystrophy show impaired GH
secretion [7,8]. The use of rhGH for the treatment of HIV-
1-associated wasting syndrome demonstrates its suitabil-
ity for routine clinical care [9,10].
The generation of fully functional virus-specific peripheral
CD4+ and CD8+ T lymphocytes in treated chronic HIV-1
infection is of considerable importance [11,12], and may
be critical for enabling control of viral activity and retard-
ing disease progression in persistent HIV-1 infection in
the presence of, and possibly following subsequent
removal of, HAART [13]. The success of immune-based
therapies will depend on full restoration of numbers and
function of the CD4+ helper T lymphocytes (HTL), anti-
gen presenting cells (APC) and CD8+ cytotoxic T lym-
phocytes (CTL) at all stages of disease [14]. Although
successful induction of HIV-1-specific T-cell responses has
been observed with various immunotherapeutic
approaches in the presence of HAART [13], the major
drawback has been that such responses were transient;
indicating that eradication of virus presents a difficult
therapeutic goal. Generation of activated virus-specific
CD4+ HTL, which may be preferentially targeted by HIV-
1, also presents the risk of de novo infection and clonal
deletion [15]. Therefore the adverse effects of HIV-1
should be taken into account when immunotherapy is
used to induce such responses. Nevertheless, induction of
HIV-1-specific T-cell responses in HIV-1-positive individ-
uals comparable to those observed in long-term nonpro-
gressors [2,16,17], remains of paramount concern.
We assessed changes in T-lymphocyte function (prolifera-
tion and IFN-γ production), thymic output and proviral
HIV-1 DNA in twelve HIV-1 infected individuals on long-
term successful HAART who received rhGH therapy for
lipodystrophy. Our data provide evidence that daily
administration of rhGH for 12 weeks dramatically
increased HIV-1-specific CD4+ HTL and CD8+ CTL
responses. This was reflected by an expansion in HIV-1-
specific CD4+ HTL proliferative responses directed to Gag,
as well as to the HIV-1 immunogen Remune™, and its
'native' p24. Responses to recombinant vaccinia virus
(rVV) constructs and overlapping peptides spanning the
HIV-1 proteins Gag and Pol were carried out using IFN-γ
ELISpot analysis to characterise HIV-1-specific CD8+ CTL
responses. Whilst reduction in dosing over a further 12
weeks resulted in the loss of virus-specific CD4+ HTL, the
virus-specific CD8+ CTL responses seen at week 12 were
sustained by week 24, and gradually declined by week 48.
Levels of T-cell receptor excision circles (TREC) and provi-
ral DNA remained constant throughout in the majority of
patients. Increases in proviral DNA were observed in only
3/12 patients. An increased anti-Nef proliferative
response was correlated to a decrease in proviral load, and
an increased anti-rVV Gag IFN-γ response correlated with
an increase in proviral load, suggesting that administra-
tion of rhGH with HAART may partially reverse some of
the damage exerted on the immune system by HIV-1.
Materials and methods
Study subjects and samples
Blood samples were taken from twelve HIV-1 infected
patients with lipodystrophy receiving HAART (9 on
NNRTI and 3 on PI based regimens) for >4 years. Mean
age ± sem was 43.4 ± 2.1 years, viral load was undetectable
in 83% (10/12) of patients, and absolute mean ± sem
CD4+ and CD8+ T-cell counts were 478.4 ± 55.6 cells/μl
and 1020.0 ± 15.6 cells/μl blood respectively (Additional
file 1). rhGH was administered to all patients for 12 weeks
at 4 mg/day (Serostim, Serono International, Geneva,
Switzerland). This was followed by randomisation into
three groups: (A) receiving placebo, (B) alternate-day dos-
ing, or (C) twice-per-week dosing of rhGH which contin-
ued for a further 12 weeks (i.e. week 24 of the study); after
which patients went back to receiving HAART alone (no
immunotherapy). Thus samples were collected at base-
line, weeks 12 and 24 of the study plus a follow up visit at
week 48 from the start of the study. The patients' informed
consent and Ethics Committee approval were obtained
for the studies described.
Plasma viral RNA assay
Viral load in patient plasma was measured at each time
point of sample collection using the Versant HIV-1 RNA
3.0 branched DNA assay (lower detection limit of 50 cop-
ies/ml plasma, Siemens Healthcare, Camberley, UK).Page 2 of 13
(page number not for citation purposes)
Journal of Immune Based Therapies and Vaccines 2008, 6:7 http://www.jibtherapies.com/content/6/1/7Antibodies, flow cytometry and lymphocyte subset 
quantification
Murine, anti-human monoclonal antibodies (mAb) to
CD3, CD4, CD8 and CD45 (TetraOne, Beckman Coulter,
High Wycombe, UK) were used to mark lymphocyte sub-
sets within whole blood and then evaluated using a
Cytomics FC 500 flow cytometer (Beckman Coulter) and
Tetra CXP (version 2.2) software.
HIV-1 antigens, peptides and recombinant vaccinia vectors 
(rVV)
HIV-1 recombinant antigens and peptides were obtained
from the Medical Research Council Centralised Facility for
AIDS Reagents (NIBSC, Potters Bar, UK), and used as pre-
viously described [17]. Cells were cultured with antigen at
final concentrations of 10 μg/ml. In addition, the inacti-
vated, gp120 depleted, HIV-1 immunogen (Remune™),
and its constituent Gag-p24 antigen ('native' p24: clade
G) (both from Immune Response Corp. Carlsbad, San
Diego, CA) were used at 3 μg/ml [18]. The 22 Gag p24
peptides were 20-mers with a 10 amino acid (aa) overlap
covering p24 Gag (aa 133–363 of HIV-1 SF2, ARP 788.1-
.22), and were used in a pool of 22 at a final concentration
of 4 μg/ml each. The 110 Pol reverse transcriptase (RT)
peptides were 15-mers with a 10 aa overlap covering RT
(HIV-1 LAI, ARP 7010.1-.110), and were used at a final
concentration of 1 μg/ml each in a pool of 110. The
recombinant vaccinia virus (rVV) constructs were
obtained through the NIH AIDS Research and Reference
Reagent Program (Rockville, MD, USA) and from the
MRC AIDS reagent project (NIBSC) and encoded Gag, Pol
or PB2 (influenza A virus basic polymerase 2 subunit
(generous gift of G. Smith); negative control) proteins.
Proliferation assays
PBMC (105/well) in 10% AB plasma/RPMI (200 μl;
Sigma, Poole, UK) were cultured in triplicate with either
antigen, mitogen or cytokine in round-bottomed micro-
titer plates (Greiner, Stonehouse, UK). Antigens, mitogens
and cytokines were used as described previously [17,19].
On day 5, each well was pulsed with 1 μCi 3H-methyl thy-
midine (3H-TdR; Amersham International, Amersham
UK) and 16 hours later cells were harvested onto glass
fibre filtermats (Wallac Oy, Turku, Finland). Proliferation,
as measured by 3H-TdR incorporation, was evaluated by
liquid scintillation spectroscopy using a 1205 Betaplate
counter (Wallac). Control wells, for calculation of back-
ground activity, contained PBMC only. Results are
expressed as stimulation index (SI) scores, which were
evaluated as the experimental result divided by the back-
ground result. A positive response is defined as an SI score
of 5 or more.
Overlapping-peptide based ELISpot assay for enumeration 
of IFNγ-producing virus-specific CD8+ T cells
PBMC at 2.5 × 105 cells/well were added to 96 well poly-
vinylidene difluoride (PVDF) backed plates (MAIP S45;
Millipore, Bedford, MA) that were previously coated with
100 μl of anti-IFN-γ mAb 1-D1k (10 μg/ml; Mabtech,
Stockholm, Sweden) and incubated overnight at 4°C.
Peptide pools or phytohaemaglutinin (PHA; positive con-
trol) at a final concentration of 10 μg/ml were added
directly to wells in 100 μl of RPMI. Negative controls com-
prised cells cultured in absence of peptide and were
always <4 spot forming cells (SFC) per 2.5 × 105 input
cells. Plates were incubated at 37°C, 5% CO2 for 16 hours
and then processed as described previously [17,19]. Spots
were counted under magnification (×20) with a Wessex
Stereomicroscope (Southern Microscopes, Maidstone,
UK) and confirmed on the Zeiss KS ELISpot system (Imag-
ing Associates, Thame, UK). Responses were considered
significant if a minimum of 5 SFC were present per well
once background was subtracted and the result was at
least double the background. Data represent mean values
of duplicate wells at each point and variation among
duplicates was <10%.
Recombinant vaccinia virus construct based ELISpot assay 
for enumeration of IFN-γ-producing virus-specific CD8+ T 
cells
Recombinant vaccinia virus constructs expressing either
HIV-1, Gag or Pol protein were used for in vitro infection
of PBMC used in the ELISpot assay. Previous studies have
demonstrated that CD8+ T cells produce >90% of the IFN-
γ release in response to rVV stimulation of PBMC [20].
PBMC were infected with rVV constructs for 1 hour at
37°C in 5% AB plasma with 20 infectious units per cell of
rVV Gag, rVV Pol and rVVPB2. Cells were washed twice in
RPMI containing 5% AB plasma (1800 rpm/5 minutes).
Finally, cells were resuspended in RPMI 10% AB plasma
and plated out in duplicate, directly onto ELISpot plates at
2.5 × 105 PBMC per well. PHA was used as positive control
and rVV PB2 was used as negative control. Detection and
enumeration of SFC was carried out as described above.
The mean values from duplicate wells were taken. A posi-
tive result is defined as at least twice the background and
a score of 5 or more above background, which was always
<20 SFC/106 PBMC.
DNA extraction and PCR analysis of sjTRECs
Extraction of DNA was carried out from 5 × 106 PBMC
using the Puregene DNA purification kit (Gentra, Flow-
gen, Staffordshire, UK). PCR amplification of signal joint
T-cell receptor excision circle (sjTREC) was carried out fol-
lowing a previously described method [21,22] and PCR
products were resolved on 1% agarose gel. A standardPage 3 of 13
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× 106 PBMC.
Latent proviral DNA: Quantification of HIV-1 DNA in 
PBMC
HIV-1 proviral DNA was measured using fluorometric
PCR methodology as previously described [23,24], with
an analytic sensitivity of 10 copies/μg of total cellular
DNA. Briefly, HIV-1 DNA levels were assessed from cryo-
preserved PBMC using the AMPLICOR HIV-1 MONITOR
(Roche Molecular Systems, Branchburg, NJ) according to
the manufacturer's instructions. All experiments were car-
ried out in duplicate and mean values used.
Statistical analysis
Computer software (GraphPad Prism® version 5.0, La
Jolla, California, USA) was used for all statistical calcula-
tions. Analysis of data between patient groups was carried
out by the Mann-Whitney test and the Wilcoxon signed
rank test was used to compare paired responses from the
same patient as appropriate. Data presented as box plots
show the median and interquartile range with whiskers
representing the 10th and 90th percentiles. Comparisons
were carried out between all time points. All statistical cal-
culations, including correlations, were calculated using
non-parametric methods. Significance was measured to a
95% confidence interval with p values below 0.05 consid-
ered significant.
Results
Twelve HIV-1 infected individuals, with chronic HIV-1
infection and lipodystrophy, receiving long-term HAART
for >4 years entered into a 48-week study. We evaluated T-
cell responses to HIV-1, and to other viral and recall anti-
gens, at baseline; after 12 weeks of daily administration of
rhGH therapy (4 mg/day subcutaneously); at 24 weeks
after randomisation into three groups: (A) placebo (B)
alternate-day dosing (C) twice-per-week dosing for weeks
12–24; and at week 48 when all patients had received
HAART alone (no immunotherapy) for the final 24 weeks
of the study. Patient characteristics at baseline, weeks 12,
24 and 48 are shown in Additional file 1. Baseline viral
load was undetectable in 10/12 patients and mean ± sem
CD4+ T-cell count was 478.4 ± 55.6 cells/μl of blood and
throughout the study viral load remained detectable in
only one patient, whilst CD4+ and CD8+ T-cell counts
remained unchanged in all patients. CD4+ HIV-1-specific
HTL responses were measured using the conventional
lymphoproliferative assay, whilst CD8+ HIV-1-specific
CTL responses were measured by ELISpot assays using
pools of overlapping peptides and rVV constructs.
While patients maintained a stable population of cells, at
baseline a complete lack of both CD4+ and CD8+ HIV-1-
specific T-cell responses was noted in 11 of 12 individuals.
After 12 weeks of daily immunotherapy with rhGH in the
presence of HAART there was a significant increase in HIV-
1-specific CD4+ T-cell proliferative responses; anti-recom-
binant p24 p = 0.0059, anti-native p24 p = 0.0140, anti-
Remune immunogen p = 0.0090 (Figure 1). This increase
was focused on Gag-specific and whole HIV-1 antigen
(Remune)-specific CD4+ T-cell responses which were pos-
itive in 9 of 12 of these patients. CD4+ and CD8+ T-cell
counts and viral load remained statistically unchanged
(Additional file 1). HIV-1-specific CD4+ HTLs were not
maintained at week 24, with less frequent dosing of
rhGH, and became undetectable in the majority of
patients by 48-week follow up (Figure 1). All figures show
the results for all 12 patients, with colours representing
the three groups post randomisation.
To address the specificity of the responses generated by
rhGH, we also assessed the CD4+ HTL responses to some
other viral [Influenza A (Flu), varicella-zoster virus (VZV),
cytomegalovirus (CMV)] and recall [tetanus toxoid
(TTox), purified protein derivative (PPD) and candida
(Can)] antigens. Daily administration of rhGH immuno-
therapy with HAART had no effect on pre-existing CD4+ T-
lymphocyte responses to Flu, CMV, PPD or Can antigens,
which was illustrated by the consistent responses directed
at these viral and recall antigens throughout the course of
study (Figure 2). Lymphoproliferative responses to VZV
and TTox were significantly increased upon daily admin-
istration of rhGH immunotherapy between time point 0
and 12 weeks (p = 0.0355 and p = 0.0078 respectively; Fig-
ure 2). High levels of lymphoproliferative responses to
herpes simplex virus (HSV) antigens were observed at
baseline and week 12, which were significantly higher
than the responses at week 24 where the responses in all
but one patient were negative (p = 0.0005 and p = 0.0059
respectively). Anti-HSV responses correlated with clinical
manifestations; despite the absence of active herpetic
lesions at time of admission, 9/12 patients in the cohort
had previous history of herpetic manifestations/complica-
tions, accounting for the strong anti-HSV lymphocyte
responses observed at baseline and week 12. In addition,
immunotherapy with daily rhGH in the presence of
HAART had no significant effect on mitogen- and IL-2-
induced lymphoproliferative responses, measured in par-
allel with antigenic responses, over a 12-week period and
throughout the course of the study (Figure 3). Daily
administration of rhGH also improved body composition
(lean body mass) [10].
Virus-specific CD8+ T-cell responses were observed at
baseline, in the absence of HIV-1-specific CD4+ T-cell
responses, in one patient only. Generally, daily adminis-
tration of rhGH, in the presence of HAART, induced a sig-
nificant increase in HIV-1-specific CD8+ T-cell responses
evaluated with rVV constructs; (Gag rVV p = 0.0059, PolPage 4 of 13
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0.0049) and Pol (p = 0.0025) proteins in IFN-γ ELISpot
assays (Figure 4). Such virus-specific CD8+ T-cell
responses were maintained at week 24 in all patients
including those who received no further rhGH. At week
48, CD8+ virus-specific T-cell responses had significantly
declined except those directed at the pool of Pol and Gag
peptides (Figure 4). There was no significant change in
IFN-γ-secreting responses to mitogenic stimulation
throughout the 48-week period (Figure 5).
To establish whether rhGH treatment induced changes in
thymic T-cell output, TREC levels were analysed in each
patient. There was no significant increase in TREC levels
between baseline and week 12 or week 24. At baseline,
week 12 and week 24 the TREC levels of groups A, B and
C were not significantly different from one another. TREC
levels, in all three groups, remained constant throughout
the course of the 24 week period of growth hormone treat-
ment (Figure 6).
Levels of proviral DNA remained constant throughout the
48-week study with no significant differences observed
between the medians at any of the time points, although
an increase was seen in three of 12 patients (Table 1).
These increases were not observed in patients in whom
plasma viral load was detectable (Additional file 1). A
negative correlation was observed between the change in
anti-Nef CD4+ T-cell proliferative response and change in
the level of HIV-1 proviral DNA between baseline and
week 12 (r2 = 0.501, p = 0.0148). The change in IFN-γ
response mounted against rVV Gag was positively corre-
lated with the change in proviral load between weeks 0
and 12 (r2 = 0.395, p = 0.0383).
Daily injections of rhGH over a 12-week period induced
both CD4+ and CD8+ HIV-1-specific T-cell responses in
HAART-treated, chronic infection. However, these bene-
fits are not maintained with less frequent dosing. There
was no significant change in thymic output, proviral load,
CD4+ T-cell count or plasma viral load as a result of daily
Proliferative CD4+ T-cell responses to HIV-1 antigens in HAART treated HIV-1-infected patients before and after rhGH immu-notherapyFigure 1
Proliferative CD4+ T-cell responses to HIV-1 antigens in HAART treated HIV-1-infected patients before and 
after rhGH immunotherapy. PBMC from 12 HIV-1-infected patients were cultured in the presence of various HIV-1 anti-
gens in triplicate for 6 days and 3H-thymidine incorporation was measured as described in materials and methods. Patient visits 
are depicted at baseline, weeks 12, 24 and 48. Results are expressed as the mean stimulation index of triplicate cultures with 
percentage error of the mean <15%. The positive threshold of an SI ≥ 5 is indicated. Box-plots show the median and IQR, and 
whiskers represent the 10th–90th percentiles. Symbols are specific to each patient according to the key shown in Additional 
file 1. Randomisation into three groups performed at week 12 is represented by different colours. Group A (red) received pla-
cebo, group B (purple) received alternate day dosing of rhGH and group C (blue) received twice weekly dosing of rhGH. Sig-
nificant p values of <0.05 are shown.
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Proliferative CD4+ T-cell responses to other viral (A) and recall (B) antigens in HAART treated HIV-1-infected patients before and after rhGH immunoth rapyFigure 2
Proliferative CD4+ T-cell responses to other viral (A) and recall (B) antigens in HAART treated HIV-1-infected 
patients before and after rhGH immunotherapy. PBMC from 12 HIV-1-infected patients were cultured in the presence 
of various viral or recall antigens in triplicate for 6 days and 3H-thymidine incorporation was measured as described in materi-
als and methods. Patient visits are depicted at baseline, weeks 12, 24 and 48. Results are expressed as the mean stimulation 
index of triplicate cultures with percentage error of the mean <15%. The positive threshold of an SI ≥ 5 is indicated. Box-plots 
show the median and IQR, and whiskers represent the 10th–90th percentiles. Symbols are specific to each patient according to 
the key shown in Additional file 1. Randomisation into three groups performed at week 12 is represented by different colours. 
Group A (red) received placebo, group B (purple) received alternate day dosing of rhGH and group C (blue) received twice 
weekly dosing of rhGH. Significant p values of <0.05 are shown.
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Journal of Immune Based Therapies and Vaccines 2008, 6:7 http://www.jibtherapies.com/content/6/1/7rhGH administration in conjunction with HAART up to
week 12, or throughout the entire course of the study
when dosing was altered according to group. An increased
anti-Nef proliferative response was correlated to a
decrease in proviral load, and an increased anti-rVV Gag
IFN-γ response correlated with an increase in proviral
load.
Discussion
HIV-1-specific CD4+ HTL and CD8+ CTL responses have
been shown to inversely correlate with viral replication
and disease progression in long-term nonprogressors and
protection from productive infection in HIV-1-infected
and exposed seronegative individuals [11,12,17,25-27].
Studies in mice have confirmed that dysfunction of CD4+
T cells affects the efficacy of CD8+ T cells in controlling
viral replication [28-30]. This forms the basis of under-
standing HIV-1 immunopathogenesis, as well as provid-
ing the rationale for the design of immunotherapeutic
strategies aimed at inducing virus-specific CD4+ and CD8+
T-cell responses, in chronic HIV-1 infection [1]. Here we
assessed the effects of rhGH therapy on the immune sys-
tem of chronically HIV-1-infected individuals, in the con-
text of long-term successful HAART. Significant increases
in both CD4+ and CD8+ HIV-1-specific T-lymphocyte
responses observed after 12 weeks of daily injections of
rhGH, concomitantly with HAART, suggest that this com-
bination appears to boost both immune reconstitution
and HIV-1-specific T-cell responses in the absence of viral
load. This dramatic effect appeared to be particularly
focused on HIV-1-specific immunity, as the CD4+ HTL
responses to other viral and recall antigens, mitogens and
IL-2 were largely unaffected. Statistically significant
increases in anti-VZV and -TTox responses were observed,
however only 3/12 individuals (anti-VZV) and 5/12 indi-
viduals (TTox) exhibited emergence of positive prolifera-
tive responses above threshold after receiving rhGH
therapy, where the response had been negative at base-
line. Significant changes in HSV responses correlate with
clinical manifestations, however no significant differences
were observed between baseline and week 12. We suggest
that, when added to HAART, rhGH immunotherapy may
target HIV-1-specific responses because these responses
are defective in ways which recall responses are not
[11,13,31-36]. Hence rhGH plays a role in resolving the
specific defect restricted to HIV-1-specific T cells.
Proliferative CD4+ T-cell responses to mitogens and IL-2 in HAART treated HIV-1-infected patients before and after rhGH immunotherapyFigure 3
Proliferative CD4+ T-cell responses to mitogens and IL-2 in HAART treated HIV-1-infected patients before 
and after rhGH immunotherapy. PBMC from 12 HIV-1-infected patients were cultured in the presence of mitogens or IL-
2 in triplicate for 6 days and 3H-thymidine incorporation was measured as described in materials and methods. Patient visits are 
depicted at baseline, weeks 12, 24 and 48. Results are expressed as the mean stimulation index of triplicate cultures with per-
centage error of the mean <15%. The positive threshold of an SI ≥ 5 is indicated. Box-plots show the median and IQR, and 
whiskers represent the 10th–90th percentiles. Symbols are specific to each patient according to the key shown in Additional 
file 1. Randomisation into three groups performed at week 12 is represented by different colours. Group A (red) received pla-
cebo, group B (purple) received alternate day dosing of rhGH and group C (blue) received twice weekly dosing of rhGH.Page 7 of 13
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dosing or twice weekly dosing at week 12, resulted in a
decline in HIV-1-specific CD4+ T-cell responses which
occurred in all patients by week 24, which was also appar-
ent at week 48. However, increases in HIV-1-specific CD8+
T-cell responses seen at week 12 were more durable as
these were maintained by week 24 regardless of randomi-
sation, and despite the apparent disappearance of HIV-1-
specific CD4+ T-cell responses. At week 48, after patients
had received HAART alone (no immunotherapy) for the
final 24 weeks of the study, HIV-1-specific CD8+ T-cell
responses specific to Pol were still above positive thresh-
old for most patients, whereas responses to other HIV-1
antigens had diminished and HIV-1-specific CD4+ T-cell
responses remained undetectable.
TREC levels remained unchanged indicating invariable
thymic output or alternatively sjTREC levels may reflect
increased division rate of naïve T cells as a result of rhGH-
induced activation. Previous observations of lower levels
of sjTRECs (per 5 × 106 PBMC) in chronic progressors may
not be entirely due to a reduction in thymic function but
could be affected by dilution of sjTRECs as a result of
immune hyperactivation-induced proliferation in these
individuals [22,37]. Assessment of both sjTRECs and
βTRECs provides an indication of the extent of intrath-
ymic proliferation [38], which determines the thymic out-
put of naïve T cells [39]. However, the analysis of ratios in
these studies has confirmed that sjTREC levels are a good
indication of thymic output, and are not hugely influ-
enced by proliferation in the periphery [22,38].
These changes were accompanied by an unexpected nota-
ble increase in proviral HIV-1 DNA in 3/12 patients by
week 24, which was maintained in only one of the
patients tested at week 48. There was a negative correla-
tion observed between the change in anti-Nef proliferative
T-cell responses and the change in levels of proviral DNA
between weeks 0 and 12. This suggests that targeting HIV-
1 Nef with a proliferative T-cell response decreases the
amount of proviral DNA/μg total DNA, reducing the
number of infected cells/HIV-1 genome copy number per
infected cell. A positive correlation was observed between
the changes in anti-rVV Gag IFN-γ response and change in
proviral DNA levels. Increased breadth and level of anti-
HIV-1 Gag IFN-γ responses have previously been shown
IFN-γ production by CD8+ T cells in response to rVV HIV-1 constructs and peptide pools in HAART treated HIV+ patients before an  af er rhGH therapyFigure 4
IFN-γ production by CD8+ T cells in response to rVV HIV-1 constructs and peptide pools in HAART treated 
HIV+ patients before and after rhGH therapy. Patient visits are depicted at baseline and at weeks 12, 24 and 48. Results 
are expressed as the mean number of SFC per 106 PBMC of duplicate cultures with <10% variation among duplicates. The pos-
itive threshold of ≥ 20 SFC per 106 PBMC is indicated. Box-plots show the median and IQR, and whiskers represent the 10th–
90th percentiles. Symbols are specific to each patient according to the key shown in Additional file 1. Randomisation into three 
groups performed at week 12 is represented by different colours. Group A (red) received placebo, group B (purple) received 
alternate day dosing of rhGH and group C (blue) received twice weekly dosing of rhGH. Significant p values of <0.05 are 
shown.
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however the effect of anti-Gag IFN-γ responses on the level
of proviral DNA has not yet been so comprehensively
investigated. A loss of response to Nef has previously been
associated with increased opportunistic infection and
viral load [41]. We have also observed that a proliferative
response to the regulatory HIV-1 protein Nef is preserved
in a cohort of HIV controllers, compared to the absence
observed in chronic progressors [17]. These findings, in
conjunction with the correlation presented here, suggest
Nef as a feasible and potentially rewarding target for
future research into effective anti-HIV-1 immune
responses.
Diminution of CD4+ T-cell responses after daily rhGH was
discontinued suggests that these cells may require stronger
and/or constant signals from rhGH to recover and provide
continuous help. CD8+ T-cell responses may be main-
tained for a limited period without CD4+ T-cell help [42],
but may eventually decline following withdrawal of rhGH
therapy. The absence of virus-specific CD4+ T-cell
responses, along with a decrease in specific CD8+ T-cell
responses by week 48, may reflect exhaustion and/or lack
of CD4+ T-cell help to facilitate the complete function of
effective HIV-1-specific CD8+ T cells [28-30]. Neverthe-
less, it is apparent that adequate HIV-1-specific CD4+ T-
cell help, provided via immunomodulatory therapy with
rhGH has 'kick-started' the appropriate effective anti-HIV-
1 CD8+ T cells.
Alternatively, the increase in fully functional HIV-1-spe-
cific CD4+ T cells (despite constant CD4+ T-cell counts)
may, in some cases, result in de novo preferential infection
of these cells as previously described [15]. Although this
may suggest a risk in the increase of the viral reservoir due
to infection of newly formed CD4+ T cells, it might also be
indicative that rhGH induces elimination of HIV-1 from
its reservoirs. The possible purgative effect of rhGH on
HIV-1 from latent reservoirs may result in de novo cellular
infections possibly accounting for some of the transient
pattern of proliferative responses observed in virus-spe-
cific CD4+ T-cell responses. This would in turn explain the
consistent levels of proviral DNA seen throughout the
study. However other explanations cannot be excluded as
it is thought that the presence of HAART should prevent
or at least minimise de novo infection of CD4+ T cells.
We have previously observed an increase in naïve CD4+
and CD8+ T cells, a significant increase in memory/effec-
tor CD8+ T cells, as well as recovery of natural killer (NK)
cell numbers and function in the same study population
of patients shown here [43,44]. Our findings provide
novel insights and extend previous observations that daily
injections of rhGH for treatment of HIV-1-associated lipo-
dystrophy result in a good outcome [45], as well as having
beneficial effects on the immune system such as inducing
thymocyte differentiation, improving function of lym-
phocytes, increasing thymic mass and directly affecting
the thymic epithelium [46-49].
It is, however, unlikely that rhGH mediates its effect by
increasing antigenic load, since the induction of HIV-1-
specific T-cell responses after 12 weeks of rhGH therapy
was seen in all patients, despite the unchangeable levels in
proviral DNA and undetectable viraemia. When consider-
ing the established mechanisms of action of rhGH, it is
suggestive that some of the beneficial effects on both the
developing thymocytes and thymic stroma may lead to
emergence of new CD4+ and CD8+ T cells with anti-HIV-1
potential (i.e. a broader T-cell repertoire). A hypothetical
model of the potential effects of rhGH on peripheral lym-
phocyte dysregulation in HIV-1 infection should, how-
ever, also be considered, as it is possible that rhGH
therapy reverses some of the negative effects on peripheral
responses of PBMC. In this respect, beneficial effects in the
periphery may be explained by the ability of rhGH to
break the HIV-1-induced T-cell dysfunction/anergy.
IFN-γ production by T cells in response to PHA in HAART treated patients at baseline a d at weeks 12, 24 a d 48Figure 5
IFN-γ production by T cells in response to PHA in 
HAART treated patients at baseline and at weeks 12, 
24 and 48. Results are expressed as the mean number of 
SFC per 106 PBMC of duplicate cultures with variation among 
duplicates <10%. The positive threshold of ≥ 20 SFC per 106 
PBMC is indicated. Box-plots show the median and IQR, and 
whiskers represent the 10th–90th percentiles. Symbols are 
specific to each patient according to the key shown in Addi-
tional file 1. Randomisation into three groups performed at 
week 12 is represented by different colours. Group A (red) 
received placebo, group B (purple) received alternate day 
dosing of rhGH and group C (blue) received twice weekly 
dosing of rhGH.Page 9 of 13
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strategies in the HAART setting (i.e. treatment interrup-
tion, IL-2 +/- therapeutic immunisation, and IL-2+GM-
CSF immunotherapy), removal of immuno- or in this case
endocrino-therapy results in loss of induced anti-HIV-1
CD4+ HTL in chronic HIV-1 infection [1,2,13].
Since plasma viral loads remained below the level of
detection at all time points, infection of such CD4+ HTL
may be the result of very low levels of viral activity unde-
tectable using current viral load assays (<50 copies/ml
plasma). Theoretically, effective drug therapy should pro-
tect HIV-1-specific CD4+ HTL once they are induced, but
this does not seem to be the case since they appear only
transiently. Ongoing viral replication in lymph nodes
(sanctuary sites, and other reservoirs) may affect the
required function of CD4+ HTL needed to subsequently
impact on the ability of virus-specific CD8+ CTL to control
HIV-1.
Endocrine and cytokine feedback mechanisms may be
operational and act beyond the parameters of the
immune system. Nevertheless this study underlines the
importance of the neuro-endocrine-immunological axis
Signal joint T-cell receptor excision circle (sjTREC) levels over the course of 24 weeksFigure 6
Signal joint T-cell receptor excision circle (sjTREC) levels over the course of 24 weeks. The number of sjTRECs/5 
× 106 PBMC was measured, as described in materials and methods, at baseline, weeks 12 and 24 after initiation of rhGH ther-
apy. Box-plots show the median and IQR, and whiskers represent the 10th–90th percentiles. Symbols are specific to each 
patient according to the key shown in Additional file 1. Randomisation into three groups performed at week 12 is represented 
by different colours. Group A (red) received placebo, group B (purple) received alternate day dosing of rhGH and group C 
(blue) received twice weekly dosing of rhGH.
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with rhGH might be associated with both de novo genera-
tion of T lymphocytes (due to increased thymic output)
[50,51] as well as increased function of HIV-1-specific T
cells (due to restored differentiation/maturation path-
ways and reversal of anergic dysfunction). In summary,
growth hormone immunotherapy and/or antigenic stim-
ulation, concomitant with HAART, may in time induce
naïve T cells, IL-2 production and response, CD4+ T-cell
proliferation, as well as both induction and maintenance
of HIV-1-specific CD8+ T cells. Larger clinical studies/trials
are warranted to fully prove clinical value.
Conclusion
It is known that loss of T-cell function occurs during HIV-
1 infection. Here we have provided evidence to demon-
strate that rhGH treatment promotes the restoration of T-
cell responses against HIV-1, a restoration that declines
with cessation of treatment. Since HIV-1+ patients com-
monly develop growth hormone abnormalities, our data
have important implications for the treatment of HIV-1,
and raise the possibility that rhGH may form part of an
immune-based therapeutic programme tailored to the
treatment of HIV-1 disease.
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